These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30593172)

  • 1. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.
    Lolli C; Medri M; Ricci M; Schepisi G; Filograna A; De Giorgi U; Stanganelli I
    Medicine (Baltimore); 2018 Dec; 97(52):e13810. PubMed ID: 30593172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced lichen planus.
    Yilmaz M; Mese SG; Celik U
    J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
    Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
    J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.
    Zekić T; Benić MS
    Rheumatol Int; 2023 Mar; 43(3):559-565. PubMed ID: 36449057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
    Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
    Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
    Liu RC; Consuegra G; Chou S; Fernandez Peñas P
    Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?
    Kus T; Aktas G
    J Oncol Pharm Pract; 2020 Jun; 26(4):1000-1004. PubMed ID: 31594517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
    Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
    Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient.
    Kalaci E; Ürün Y
    J Oncol Pharm Pract; 2023 Oct; 29(7):1797-1801. PubMed ID: 37401253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.
    Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T
    Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
    Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
    Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
    Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
    In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vitiligo under checkpoint inhibitors].
    Amini-Adle M; Dalle S
    Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
    Escudier B; Motzer RJ; Sharma P; Wagstaff J; Plimack ER; Hammers HJ; Donskov F; Gurney H; Sosman JA; Zalewski PG; Harmenberg U; McDermott DF; Choueiri TK; Richardet M; Tomita Y; Ravaud A; Doan J; Zhao H; Hardy H; George S
    Eur Urol; 2017 Sep; 72(3):368-376. PubMed ID: 28410865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.